.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,127,334

« Back to Dashboard

Details for Patent: 6,127,334

Title: Methods for producing biphasic insulin formulations
Abstract:Insulin preparations of superior physical stability, comprising dissolved and/or precipitated human insulin or an analogue or derivative thereof, and a water-soluble reduced or non-reducing carbohydrate containing at least 4 carbon atoms in the main carbohydrate structure, or a water-soluble non-reducing ester and/or ether derivative of a carbohydrate or reduced carbohydrate containing at least 4 carbon atoms in the main carbohydrate structure, or mixtures thereof are disclosed.
Inventor(s): Kimer; Lone L.o slashed.gstrup (Farum, DK), Balschmidt; Per (Esperg.ae butted.rde, DK), Jensen; Steen (Drag.o slashed.r, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Filing Date:Nov 24, 1998
Application Number:09/198,878
Claims:1. A method for preparing an insulin product, comprising the steps of:

(a) providing an acidic solution comprising an insulin analogue, a source of zinc, and a sub-isophanic amount of protamine, wherein the weight ratio of the insulin analogue to protamine in the acidic solution results in a weight ratio of dissolved to precipitated insulin analogue in the range of 20:80 to 80:20 in the insulin product;

(b) providing an alkaline solution comprising a substance which acts as a buffer at physiological pH; wherein at least one of the solutions of steps (a) and (b) further comprises a phenolic compound;

(c) mixing the acidic and alkaline solutions to form a suspension; and

(d) leaving the suspension to form the insulin product which comprises a soluble phase comprising the insulin analogue and a solid phase comprising the precipitated insulin analogue.

2. The method of claim 1, wherein the weight ratio of the insulin analogue in the final product is between 30:70 to 70:30.

3. The method of claim 1, wherein the source of zinc is zinc chloride.

4. The method of claim 1, wherein the source of zinc is present in an amount corresponding to 10-40 .mu.g zinc/100 IU insulin.

5. The method of claim 4, wherein the source of zinc is present in an amount corresponding to 15-35 .mu.g zinc/100 IU insulin.

6. The method of claim 1, wherein the acidic solution of step (a) and/or the alkaline solution of step (b) further comprises chloride in an amount corresponding to 0 to 100 mM in the final product.

7. The method of claim 6, wherein the chloride is present in an amount corresponding to 5 to 20 mM in the final product.

8. The method of claim 6, wherein the chloride is sodium chloride.

9. The method of claim 1, wherein the pH of the acidic solution of step (a) is below 5.

10. The method of claim 9, wherein the pH of the acidic solution of step (a) is in the range of 2 to 3.5.

11. The method of claim 1, wherein the insulin analogue is selected from the group consisting of: (i) human insulin wherein position B28 is Asp, Lys, Leu, Val or Ala and position B29 is Lys or Pro; (ii) des (B28-B30) human insulin; des(B27) human insulin; and des(B30) human insulin.

12. The method of claim 11, wherein the insulin analogue is Asp.sup.B28 human insulin.

13. The method of claim 11, wherein the insulin analogue is Lys.sup.B28 Pro.sup.B29 human insulin.

14. The method of claim 1, wherein the phenolic compound is selected from the group consisting of phenol, m-cresol or a mixture thereof.

15. The method of claim 1, wherein the acidic solution of step (a) and/or the alkaline solution of step (b) further comprises a water-soluble reduced or non-reducing carbohydrate containing at least 4 carbon atoms in the main carbohydrate structure, or a water-soluble non-reducing ester and/or ether derivative of a carbohydrate or reduced carbohydrate containing at least 4 carbon atoms in the main carbohydrate structure, or mixtures thereof.

16. The method of claim 15, wherein the carbohydrate or carbohydrate derivative contains from 5 to 18 carbon atoms in the main carbohydrate structure.

17. The method of claim 16, wherein the carbohydrate or carbohydrate derivative is mannitol, sorbitol, xylitol, trehalose, sucrose or any mixture thereof.

18. The method of claim 1, wherein the buffer substance employed in the alkaline solution of step (b) is a physiologically tolerated buffer.

19. The method of claim 1, wherein the precipitated insulin analogue is in the form of crystals comprising insulin analogue and protamine.

20. The method of claim 1, wherein the suspension obtained in step (c) is left at a temperature in the range of 5.degree. C. to 40.degree. C. for precipitation.

21. The method of claim 1, further comprising adjusting the pH of the mixture of the acidic and alkaline solutions of step (c) to a value in the range of 6.5 to 8.0.

22. The method of claim 21, wherein the pH is adjusted to 7.0 to 7.8.

23. The method of claim 1, wherein the precipitated insulin analogue is in the form of crystals.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc